Independent Voters’ Approval Rating Of Donald Trump Plummets, Latest Poll Indicates
President Donald Trump’s approval rating has seen a notable dip among independent voters, as indicated by a new Gallup survey. read more
President Donald Trump’s approval rating has seen a notable dip among independent voters, as indicated by a new Gallup survey. read more
A long-dormant Bitcoin (CRYPTO: BTC) whale has resurfaced after more than 14 years of inactivity, moving a whopping $469.8 million in Bitcoin, as per recent on-chain data. read more
Sen. Cynthia Lummis (R-Wyo.) has been advocating for Bitcoin (CRYPTO: BTC), asserting its importance for the U.S. economy and its citizens. What Happened: During an interview, Lummis communicated her belief that Bitcoin is more than a speculative asset. read more
A renowned cryptocurrency trader has forecasted a substantial surge for Dogecoin (CRYPTO: DOGE). What Happened: Ali Martinez, a widely followed crypto analyst, has projected a 109% rise for Dogecoin if it manages to regain a crucial support level. read more
Trump kicks off a four-day visit to Scotland, calling it “great to be in Scotland” as he mixes politics, golf, and diplomacy. read more
Jamie Dimon, recently shared a personal anecdote about the day he was fired from Citigroup and the impact it had on his family and career. read more
Last week, former White House Communications Director Anthony Scaramucci offered a surprising assessment of Donald Trump, calling his political comeback historic and cautioning critics not to confuse his communication style with a lack of intelligence. read more
Rep. Marjorie Taylor Greene (R-Ga.) has been one of the most active stock investors from the political fraternity, and several of her trades have received significant media attention. read more
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the reasons why and what’s next. read more
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. read more